We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+8.78%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.32B
AUM Growth
-$52.2M
Cap. Flow
-$44.2M
Cap. Flow %
-1.9%
Top 10 Hldgs %
73.45%
Holding
41
New
1
Increased
16
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.8M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$19.8M
3
INSM icon
Insmed
INSM
+$6.88M
4
EPZM
Epizyme, Inc
EPZM
+$6.72M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.16M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$65.3M
2
UTHR icon
United Therapeutics
UTHR
+$19.9M
3
FOLD
Amicus Therapeutics
FOLD
+$19.4M
4
EXAS
Exact Sciences
EXAS
+$6.52M
5
AIMT
Aimmune Therapeutics
AIMT
+$4.75M

Sector Composition

Rank Sector Weight
1 Healthcare 92.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIVV
26
DELISTED
Bioverativ Inc. Common Stock
BIVV
$14.3M 0.61%
264,400
+53,100
+25% +$2.91M
GILD icon
27
Gilead Sciences
GILD
$170B
$12.6M 0.54%
175,900
– –
DRNA
28
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.52M 0.19%
500,913
– –
VIRX
29
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.29M 0.18%
33,214
– –
ALIM
30
DELISTED
Alimera Sciences
ALIM
$4.01M 0.17%
200,920
– –
ACGN
31
DELISTED
Aceragen Inc
ACGN
$1.3M 0.06%
4,537
– –
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
$1.18M 0.05%
29,500
– –
CYTK icon
33
Cytokinetics
CYTK
$10.3B
$1.01M 0.04%
123,686
– –
MLNT
34
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$801K 0.03%
+10,138
New +$750K
OCGN icon
35
Ocugen
OCGN
$458M
$621K 0.03%
5,049
– –
SPHS
36
DELISTED
Sophiris Bio, Inc.
SPHS
$561K 0.02%
247,000
– –
TRVN
37
DELISTED
Trevena, Inc.
TRVN
$546K 0.02%
546
– –
ARCT icon
38
Arcturus Therapeutics
ARCT
$222M
– –
-38,970
Closed -$276K
SLNO
39
DELISTED
Soleno Therapeutics
SLNO
– –
-1,130
Closed -$220K
TLPH icon
40
Talphera
TLPH
$62.3M
– –
-51,636
Closed -$4.75M
CEMP
41
DELISTED
Cempra, Inc.
CEMP
– –
-340,320
Closed -$1.11M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return

Palo Alto Investors's Q4 2017 Portfolio in Review

As of Q4 2017, Palo Alto Investors held 41 positions worth $2.32B, down 2.2% from $2.37B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Palo Alto Investors's Q4 2017 filing shows 1 new, 16 increased, 7 reduced and 4 closed positions. Its largest new stake was Melinta Therapeutics, Inc. Common Stock: 10,138 shares worth $801K. The largest sale was Abiomed Inc, an estimated $65.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier.

  • Palo Alto Investors's largest Q4 2017 buy was Melinta Therapeutics, Inc. Common Stock: 10,138 shares worth $801K.
  • Palo Alto Investors added most to Immunomedics Inc in Q4 2017, an estimated $20.8M increase.
  • Palo Alto Investors's biggest Q4 2017 reduction was Abiomed Inc, cutting an estimated $65.3M.
  • Palo Alto Investors fully exited Talphera in Q4 2017, selling an estimated $4.75M.
  • Palo Alto Investors's ten largest holdings make up 73% of its $2.32B portfolio in Q4 2017.
  • Palo Alto Investors opened 1 new position and closed 4 in Q4 2017.
  • Palo Alto Investors's portfolio value fell 2.2% quarter-over-quarter to $2.32B.

Based on Palo Alto Investors's 13F filing for Q4 2017, filed 14 Feb 2018.